StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) company profile

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

About Puma Biotechnology

Pharmaceutical Preparations, SIC 2834

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products for cancer care. Its primary commercial product is Nerlynx, an oral tablet formulation of neratinib used to treat specific forms of HER2-positive breast cancer. In addition, the company is developing alisertib, an in-licensed selective small-molecule inhibitor of Aurora Kinase A for potential use against lung and breast cancers. Puma Biotechnology serves healthcare providers and cancer patients requiring targeted oncology treatments.

The company maintains its principal executive offices in Los Angeles, California. In the United States, it markets its commercial drug through a direct specialty sales team of roughly 35 sales specialists. Globally, the company relies on third-party sub-license partners to handle regulatory filings and commercialization. Through these international partnerships, Nerlynx holds regulatory approvals in more than forty countries, including Canada, Australia, China, and member states of the European Union.

Summary of the business section of Puma Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Puma Biotechnology, Inc.
Headquarters
Los Angeles, CA
Address
10880 Wilshire Blvd., Suite 1700
Phone
(424) 248-6500
Employees
179, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Los Angeles, CA

Stock & identifiers

Ticker
PBYI
Exchange
Nasdaq
IPO date
Apr 24, 2012
Shares outstanding
52M, Aug 3, 2026
Public float
$145.20M, Jun 30, 2025
Filer category
Accelerated filer<br>Smaller reporting company
SEC CIK
1401667
CUSIP
74587V107
ISIN
US74587V1070
FIGI
BBG0018YXYX7
Share class FIGI
BBG001TFZB81
EIN
77-0683487

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alan H. AuerbachPresident and CEO, Director7,261,671
Maximo F. NouguesChief Financial Officer230,637
Douglas M. HuntSee Remarks196,841
Jeffrey Jerome LudwigChief Commercial Officer156,792
Michael Patrick MillerDirector66,000
Troy Edward WilsonDirector55,300
Alessandra CesanoDirector118,850
Allison DorvalDirector90,780
Adrian SenderowiczDirector27,000
Brian M. StuglikDirector113,858
Jay M. MoyesDirector58,322

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.06M$4.43M$1.26M$58$125
FY2024$3.97M$2.55M$1.30M$30$93
FY2023$2.94M$2.80M$1.22M$42$94
FY2022$2.53M$3.25M$982.21K$41$90
FY2021$18.45M$14.67M$1.48M$30$100
FY2020$4.41M$3.97M$1.93M$117$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Alan H. Auerbach
President and Chief Executive Officer
$931.33K–$551.55K$535.51K$1.03M$16.64K$3.06M-23%
Maximo F. Nougues
Chief Financial Officer
$562.96K$130.61K$170.85K$165.88K$191.07K$19.85K$1.24M-12%
Jeff J. Ludwig
Chief Commercial Officer
$264.88K–$133.00K$129.13K–$949.16K$1.48M+20%
Douglas Hunt
Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer
$489.06K$122.27K$133.77K$129.88K$165.99K$20.45K$1.06M-13%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, our workforce consisted of 179 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?